Laxatives for Patients with Impaired Renal Function

First-Line Options for Renal Impairment

The American Society of Clinical Oncology recommends Polyethylene glycol (PEG) as the safest option for patients with renal impairment due to minimal systemic absorption and good safety profile in elderly patients 1
Stimulant laxatives (senna, bisacodyl) are generally safe in renal impairment as they work locally in the intestine with minimal systemic absorption, according to the National Comprehensive Cancer Network 2, 3

Magnesium-containing laxatives (magnesium hydroxide, magnesium citrate) should be used cautiously or avoided in renal impairment due to risk of hypermagnesemia, as warned by the American Gastroenterological Association 2, 4
Sodium phosphate preparations should be avoided in renal impairment due to risk of electrolyte disturbances and potential for acute phosphate nephropathy, according to the National Comprehensive Cancer Network 3

For mild to severe renal impairment, the first choice is PEG (17g/day), which offers an efficacious and tolerable solution with a good safety profile, as recommended by the American Society of Clinical Oncology 1, 4
Alternative options include stimulant laxatives (senna, bisacodyl), which are effective for short-term use or as rescue therapy, according to the American Society of Clinical Oncology 5, 4

For opioid-induced constipation in patients with renal impairment, stimulant laxatives or PEG are preferred, as recommended by the National Comprehensive Cancer Network 3, 6
Bulk laxatives such as psyllium are not recommended for opioid-induced constipation, according to the American Society of Clinical Oncology 6

Magnesium-containing laxatives can accumulate in patients with renal impairment, leading to hypermagnesemia, as warned by the American Gastroenterological Association 2, 4
Sodium phosphate enemas can cause severe electrolyte disturbances and acute phosphate nephropathy in patients with renal impairment, according to the National Comprehensive Cancer Network 3
Bulk-forming laxatives should be avoided in non-ambulatory patients with low fluid intake due to risk of intestinal obstruction, as recommended by the American Society of Clinical Oncology 1

Regular assessment of renal function and electrolytes is recommended when using laxatives in patients with kidney disease, according to the American Society of Clinical Oncology 1
Particular attention should be paid to hydration status, especially in patients taking osmotic laxatives, and monitoring for drug interactions is crucial, especially with concomitant diuretics or cardiac glycosides, as recommended by the American Society of Clinical Oncology 1

Bisacodyl suppositories can be used rectally if local stimulation is needed, as they avoid the phosphate toxicity risk, according to the Annals of Oncology 7

Fleet enemas are absolutely contraindicated in patients with bowel obstruction, ileus, recent colorectal surgery, inflammatory bowel disease, recent pelvic radiation, neutropenia, thrombocytopenia, elderly patients, and children under 2 years, as stated in the Annals of Oncology 7

If rectal intervention is needed after oral laxatives fail, bisacodyl suppositories or small-volume tap water/saline enemas can be used, but never sodium phosphate, as recommended by the Annals of Oncology 7

The European Society for Medical Oncology (ESMO) guidelines recommend lactulose as a safe option for patients with renal impairment because it is not absorbed by the small bowel and works through local osmotic effects in the colon 8
Lactulose is an appropriate alternative to polyethylene glycol (PEG) for ESRD patients, with a dose of 10-20g or 15-30mL daily, and can be increased up to 40g daily if needed 9
Stool softeners like docusate are generally not recommended in advanced disease according to ESMO guidelines, and lack robust clinical trial data supporting their effectiveness 8

The American Gastroenterological Association recommends starting with PEG (17g/day) as the optimal first choice for ESRD patients, but lactulose (10-20g or 15-30mL daily) is an appropriate alternative if PEG is unavailable or not tolerated 9
Stimulant laxatives (senna, bisacodyl) are safe alternatives in renal impairment as they work locally in the intestine with minimal systemic absorption, and can be used short-term (≤4 weeks) or as rescue therapy 9

Lactulose improved constipation symptoms, including cramping, griping, flatulence, tenesmus, and bloating, significantly better than placebo (p<0.04) 10, 11
Lactulose and PEG were superior to placebo in improving bowel consistency in opioid-induced constipation trials 10, 11

The European Society for Medical Oncology (ESMO) guidelines advise against using docusate in advanced disease and ESRD populations due to lack of evidence 8
Regular assessment of renal function and electrolytes is essential when using any laxative in kidney disease, and monitoring for drug interactions is crucial, especially with concomitant diuretics or cardiac glycosides 9